- 7Apr, 2026
For decades, infections like gonorrhea and chlamydia were treated as routine; a quick course of antibiotics and life went on. Now, that comfort is collapsing. Neisseria gonorrhoeae has steadily outmaneuvered drug after drug, such as macrolides, fluoroquinolones and more;1 and today we rely on a [...]
$2.9 Million NIH Grant for Novel Investigational Therapeutic to Combat Antibiotic-Resistant Gonorrhea
TAXIS has received a $2.9 million grant to further advance R&D efforts for its dihydrofolate reductase inhibitors (DHFRIs) as a novel approach to combat multi-drug resistant gonorrhea, a rapidly spreading deadly and highly resistant strain of Neisseria gonorrhoeae.
- 17Dec, 2024
Understanding the mechanisms behind antibiotic resistance reveals the pressing need for innovative solutions in the pharmaceutical landscape. Presenting TAXIS Pharmaceuticals' Commitment to Innovation: TXA709. TAXIS is dedicated to developing novel therapies that specifically target resistant strains of bacteria.
- 18Nov, 2024
Our new white paper delves into the global scope of AMR, shedding light on its widespread impact and the variability of its effects across different regions. The paper outlines actionable strategies to combat AMR, such as enhancing global surveillance systems, advocating for responsible antibiotic use, investing in the development of innovative treatments, and fostering international collaboration.
- 14Oct, 2024
The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies. This article was originally published on contagionlive.com.
